Drug intelligence / Profile preview

mFNDC1

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes

Overview

mFNDC1 is a recombinant truncated mouse fibronectin type III domain containing 1 (FNDC1), identified as a myokine that plays a crucial role in myogenesis and muscle regeneration. It promotes myoblast differentiation and myotube formation. Mechanistically, mFNDC1 binds to integrin α5β1, which subsequently activates the downstream FAK/PI3K/AKT/mTOR pathway. This activation leads to enhanced myogenic differentiation and muscle regeneration. Preclinical studies have shown that mFNDC1 treatment can ameliorate pathological muscle phenotypes in the mdx mouse model of Duchenne muscular dystrophy, suggesting its potential as a therapeutic agent for acute and chronic muscle diseases.

Other names: recombinant truncated mouse FNDC1

Targets

ITGA5:ITGB1 (Integrin α5β1)

Beyond the preview

Go deeper on mFNDC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mFNDC1.

Explore the full profile